Free tool
FAERS Monitor: Triumeq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205551 or its brand name (Triumeq, Abacavir Sulfate, Dolutegravir Sodium, Lamivudine). Reports on generic versions are filed under their own applications.
Reports
6,334
Serious
3,413
54% of reports
Hospitalization
1,195
Death reported
329
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue827
- pain809
- anxiety757
- emotional distress697
- anhedonia628
- chronic kidney disease473
- fatigue336
- depression315
- renal failure309
- nausea306
- osteoporosis282
- headache264
- bone density decreased257
- economic problem230
- insomnia227
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 326 |
| 2016 | 658 |
| 2017 | 717 |
| 2018 | 806 |
| 2019 | 784 |
| 2020 | 723 |
| 2021 | 460 |
| 2022 | 548 |
| 2023 | 498 |
| 2024 | 419 |
| 2025 | 320 |
| 2026 | 68 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,825 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anhedoniaSignal | 628 | 81.3 | 75.4 | 48,581 |
| economic problemSignal | 230 | 51.1 | 45.0 | 11,096 |
| bone density decreasedSignal | 257 | 27.5 | 24.3 | 6,481 |
| osteoporosisSignal | 282 | 22.9 | 20.4 | 5,860 |
| chronic kidney diseaseSignal | 473 | 20.8 | 19.1 | 8,870 |
| emotional distressSignal | 697 | 19.2 | 17.9 | 12,022 |
| product dose omission issueSignal | 827 | 9.4 | 8.8 | 6,238 |
| anxietySignal | 757 | 8.9 | 8.3 | 5,324 |
| renal failureSignal | 309 | 7.7 | 6.9 | 1,815 |
| depressionSignal | 315 | 4.6 | 4.1 | 893 |
| painSignal | 809 | 4.4 | 4.1 | 2,165 |
| insomniaSignal | 227 | 2.8 | 2.5 | 270 |
| fatigue | 336 | 1.4 | 1.3 | 45 |
| headache | 264 | 1.4 | 1.2 | 30 |
| nausea | 306 | 1.3 | 1.2 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.